Logo image of HTGM

HTG MOLECULAR DIAGNOSTICS (HTGM) Stock Fundamental Analysis

USA - NASDAQ:HTGM - US40434H3021 - Common Stock

0.48 USD
-0.12 (-20%)
Last: 6/14/2023, 8:00:02 PM
0.4815 USD
+0 (+0.31%)
After Hours: 6/14/2023, 8:00:02 PM
Fundamental Rating

1

HTGM gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. HTGM has a bad profitability rating. Also its financial health evaluation is rather negative. HTGM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

HTGM had negative earnings in the past year.
HTGM had a negative operating cash flow in the past year.
In the past 5 years HTGM always reported negative net income.
In the past 5 years HTGM always reported negative operating cash flow.
HTGM Yearly Net Income VS EBIT VS OCF VS FCFHTGM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M -20M -25M

1.2 Ratios

HTGM has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HTGM Yearly ROA, ROE, ROICHTGM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400 600

1.3 Margins

The Gross Margin of HTGM (21.69%) is worse than 79.55% of its industry peers.
In the last couple of years the Gross Margin of HTGM has declined.
HTGM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.29%
GM growth 5Y-15.73%
HTGM Yearly Profit, Operating, Gross MarginsHTGM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -200 -400

1

2. Health

2.1 Basic Checks

HTGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HTGM has been increased compared to 1 year ago.
The debt/assets ratio for HTGM has been reduced compared to a year ago.
HTGM Yearly Shares OutstandingHTGM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
HTGM Yearly Total Debt VS Total AssetsHTGM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -35.30, we must say that HTGM is in the distress zone and has some risk of bankruptcy.
HTGM's Altman-Z score of -35.30 is on the low side compared to the rest of the industry. HTGM is outperformed by 90.91% of its industry peers.
A Debt/Equity ratio of 7.10 is on the high side and indicates that HTGM has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 7.10, HTGM is doing worse than 75.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 7.1
Debt/FCF N/A
Altman-Z -35.3
ROIC/WACCN/A
WACC4.37%
HTGM Yearly LT Debt VS Equity VS FCFHTGM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 1.40 indicates that HTGM should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.40, HTGM is doing worse than 61.36% of the companies in the same industry.
A Quick Ratio of 1.30 indicates that HTGM should not have too much problems paying its short term obligations.
HTGM has a worse Quick ratio (1.30) than 61.36% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.3
HTGM Yearly Current Assets VS Current LiabilitesHTGM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.99% over the past year.
The Revenue for HTGM has decreased by -28.21% in the past year. This is quite bad
HTGM shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -15.48% yearly.
EPS 1Y (TTM)44.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.54%
Revenue 1Y (TTM)-28.21%
Revenue growth 3Y-30.79%
Revenue growth 5Y-15.48%
Sales Q2Q%-12.83%

3.2 Future

The Earnings Per Share is expected to grow by 39.92% on average over the next years. This is a very strong growth
HTGM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.55% yearly.
EPS Next Y81.55%
EPS Next 2Y39.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.6%
Revenue Next 2Y53.55%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HTGM Yearly Revenue VS EstimatesHTGM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
HTGM Yearly EPS VS EstimatesHTGM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HTGM. In the last year negative earnings were reported.
Also next year HTGM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HTGM Price Earnings VS Forward Price EarningsHTGM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HTGM Per share dataHTGM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as HTGM's earnings are expected to grow with 39.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.92%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for HTGM!.
Industry RankSector Rank
Dividend Yield N/A

HTG MOLECULAR DIAGNOSTICS

NASDAQ:HTGM (6/14/2023, 8:00:02 PM)

After market: 0.4815 +0 (+0.31%)

0.48

-0.12 (-20%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-10 2023-05-10/amc
Earnings (Next)08-09 2023-08-09/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners201.96%
Ins Owner Change0%
Market Cap1.06M
Revenue(TTM)6.21M
Net Income(TTM)-20.15M
Analysts82.86
Price Target6.12 (1175%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-48.59%
Min EPS beat(2)-81.95%
Max EPS beat(2)-15.22%
EPS beat(4)2
Avg EPS beat(4)-14.95%
Min EPS beat(4)-81.95%
Max EPS beat(4)24.87%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-19.27%
Min Revenue beat(2)-36.73%
Max Revenue beat(2)-1.8%
Revenue beat(4)0
Avg Revenue beat(4)-34.25%
Min Revenue beat(4)-56.97%
Max Revenue beat(4)-1.8%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-40%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-162.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-67.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-28.89%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-34.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.17
P/FCF N/A
P/OCF N/A
P/B 2.24
P/tB 2.24
EV/EBITDA N/A
EPS(TTM)-18.15
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-7.61
FCFYN/A
OCF(TTM)-7.6
OCFYN/A
SpS2.81
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.69%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.29%
GM growth 5Y-15.73%
F-Score3
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 7.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.28%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 1.3
Altman-Z -35.3
F-Score3
WACC4.37%
ROIC/WACCN/A
Cap/Depr(3y)42.2%
Cap/Depr(5y)55.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.54%
EPS Next Y81.55%
EPS Next 2Y39.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-28.21%
Revenue growth 3Y-30.79%
Revenue growth 5Y-15.48%
Sales Q2Q%-12.83%
Revenue Next Year0.6%
Revenue Next 2Y53.55%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.73%
OCF growth 3YN/A
OCF growth 5YN/A

HTG MOLECULAR DIAGNOSTICS / HTGM FAQ

What is the ChartMill fundamental rating of HTG MOLECULAR DIAGNOSTICS (HTGM) stock?

ChartMill assigns a fundamental rating of 2 / 10 to HTGM.


Can you provide the valuation status for HTG MOLECULAR DIAGNOSTICS?

ChartMill assigns a valuation rating of 1 / 10 to HTG MOLECULAR DIAGNOSTICS (HTGM). This can be considered as Overvalued.


How profitable is HTG MOLECULAR DIAGNOSTICS (HTGM) stock?

HTG MOLECULAR DIAGNOSTICS (HTGM) has a profitability rating of 1 / 10.


How financially healthy is HTG MOLECULAR DIAGNOSTICS?

The financial health rating of HTG MOLECULAR DIAGNOSTICS (HTGM) is 1 / 10.